Scientific Publications Featuring PET/MR

Scientific publications featuring PET/MR technology, highlighting research applications, methods, and findings using PET/MR imaging.
TitleAuthorsLink to PaperSummary
Yttrium-86 is a positron emitting surrogate of gadolinium for noninvasive quantification of whole-body distribution of gadolinium-based contrast agentsLe Fur M, Rotile NJ, Correcher C, Clavijo Jordan V, Ross AW, Catana C, Caravan POpen paperThis paper uses the PET isotope yttrium-86 as a surrogate for gadolinium to quantify the whole-body distribution of gadolinium-based MRI contrast agents.
Kidney glycolysis serves as a mammalian phosphate sensor that maintains phosphate homeostasisZhou W, Simic P, Zhou IY, Caravan P, Vela Parada X, Wen D, Washington OL, Shvedova M, Pierce KA, Clish CB, et alOpen paperThis study examines kidney glucose metabolism as a phosphate-sensing mechanism, using imaging-related metabolic assessment to investigate phosphate homeostasis.
Development of a fibrin-targeted theranostic for gastric cancerEsfahani SA, et alOpen paperThis paper develops a fibrin-targeted theranostic for gastric cancer, combining molecular targeting with an imaging approach suitable for PET-based disease assessment.
Positron emission tomography-magnetic resonance imaging pharmacokinetics, in vivo biodistribution, and whole-body elimination of Mn-PyC3AZhou IY, Ramsay IA, Ay I, Pantazopoulos P, Rotile NJ, Wong A, Caravan P, Gale EMOpen paperThis PET/MRI study characterizes the pharmacokinetics, biodistribution, and whole-body elimination of the manganese-based contrast agent Mn-PyC3A.
Characterization of a preclinical PET insert in a 7 tesla MRI scanner: beyond NEMA testingGsell W, Molinos C, Correcher C, Belderbos S, Wouters J, Junge S, Heidenreich M, Vande Velde G, Rezaei A, Nuyts J, et alOpen paperThis technical study evaluates a preclinical PET insert operating inside a 7 T MRI scanner, extending performance assessment beyond standard NEMA testing.
In vitro and in vivo characterization of [64Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumorsLiu T, Dahle M, Lystad MH, Marignol L, Karlsen M, Redalen KROpen paperThis paper evaluates copper-64-labeled elesclomol as a PET theranostic agent for imaging and potentially treating hypoxic solid tumors.
CD38-specific gallium-68 labeled peptide radiotracer enables pharmacodynamic monitoring in multiple myeloma with PETSharma AK, Gupta K, Mishra A, Lofland G, Marsh I, Kumar D, Ghiaur G, Imus P, Rowe SP, Hobbs RF, et alOpen paperThis study uses a gallium-68-labeled CD38-specific PET tracer to monitor pharmacodynamic response in multiple myeloma.
A practical method for multimodal registration and assessment of whole-brain disease burden using PET, MRI, and optical imagingScarpelli ML, Healey DR, Mehta S, et alOpen paperThis paper presents a multimodal registration method that integrates PET, MRI, and optical imaging to assess whole-brain disease burden.
Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studiesEsfahani SA, Ma H, Krishna S, Shuvaev S, Sabbagh M, Deffler C, Rotile N, Weigand-Whittier J, Zhou IY, Catana C, et alOpen paperThis translational study uses collagen type I PET/MRI to evaluate treatment response in pancreatic cancer across preclinical and first-in-human investigations.
Novel approach using [18F]FTHA-PET and de novo synthesized VLDL for assessment of FFA metabolism in a rat model of diet-induced NAFLDUstsinau U, Ehret V, Fürnsinn C, Scherer T, Helbich TH, Hacker M, Krššák M, Philippe COpen paperThis study applies [18F]FTHA PET together with newly synthesized VLDL to assess free-fatty-acid metabolism in a rat model of diet-induced fatty liver disease.
Hyperpolarized [1-13C]pyruvate magnetic resonance spectroscopic imaging for evaluation of early response to tyrosine kinase inhibition therapy in gastric cancerEsfahani SA, Callahan C, Rotile NJ, Heidari P, Mahmood U, Caravan PD, Grant AK, Yen YFOpen paperThis paper uses hyperpolarized [1-13C]pyruvate MR spectroscopic imaging to detect early metabolic response to tyrosine kinase inhibitor therapy in gastric cancer.
Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe3O4@Al(OH)3 nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distributionBelderbos S, González-Gómez MA, Cleeren F, Wouters J, Piñeiro Y, Deroose CM, et alOpen paperThis simultaneous PET/MRI study compares the in vivo distribution of fluorine-18-labeled iron oxide nanoparticles with that of stem cells labeled using the same nanoparticles.
Simultaneous positron emission tomography and molecular magnetic resonance imaging of cardiopulmonary fibrosis in a mouse model of left ventricular dysfunctionMoon BF, Zhou IY, Ning Y, Chen YCI, Le Fur M, Shuvaev S, et alOpen paperThis study combines PET and molecular MRI to visualize cardiopulmonary fibrosis in a mouse model of left ventricular dysfunction.
Radiocaine: an imaging marker of neuropathic injuryBartolo ND, Reid SE, Krishnan HS, Haseki A, Renganathan M, Largent-Milnes TM, Norwood BA, Loggia ML, Hooker JMOpen paperThis paper evaluates Radiocaine as a PET imaging marker for detecting neuropathic injury.
GMP-compliant fully automated radiosynthesis of [18F]FEPPA for PET/MRI imaging of regional brain TSPO expressionChang CW, Chiu CH, Lin MH, Wu HM, Yu TH, Wang PY, Kuo YY, Huang YY, Shiue CY, Huang WS, Yeh SHOpen paperThis paper describes an automated GMP-compliant synthesis of [18F]FEPPA for PET/MRI measurement of regional TSPO expression in the brain.
HER3 PET imaging predicts response to pan receptor tyrosine kinase inhibition therapy in gastric cancerEsfahani SA, de Aguiar Ferreira C, Rotile NJ, Ataeinia B, Krishna S, Catalano OA, Caravan P, Yen YF, Heidari P, Mahmood UOpen paperThis study uses HER3-targeted PET imaging to predict response to broad receptor tyrosine kinase inhibition in gastric cancer.
Automated GMP-compliant production of [18F]AlF-NOTA-octreotideTshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, Deroose CM, Cleeren FOpen paperThis paper describes automated GMP-compliant production of [18F]AlF-NOTA-octreotide, a radiotracer intended for somatostatin-receptor PET imaging.
Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic MN-anti-miR10b demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancerLe Fur M, Ross A, Pantazopoulos P, Rotile N, Zhou IY, Caravan P, Medarova Z, Yoo BOpen paperThis study uses PET/MRI microdosing to demonstrate delivery of the experimental MN-anti-miR10b cancer therapeutic to metastatic breast cancer lesions in mice.
Development and preclinical evaluation of [211At]PSAt-3-Ga: an inhibitor for targeted α-therapy of prostate cancerEl Fakiri M, Ayada N, Müller M, Hvass L, Gamzov TH, Clausen AS, et alOpen paperThis paper develops and preclinically evaluates the astatine-211 compound PSAt-3-Ga for targeted alpha therapy of prostate cancer, with radiolabeling supporting nuclear-medicine assessment.
Targeted dual-modality imaging of inflammation using 18F-radiolabeled iron oxide microparticlesGuillou A, Pedron S, Alhaddad N, Bonnard T, Martinez de Lizarrondo S, Gauberti M, Vivien D, Perrio COpen paperThis paper develops an 18F-radiolabeled iron oxide microparticle platform for targeted dual-modality imaging of inflammation, combining PET sensitivity with magnetic particle contrast.
Novel [18F]fluorine-based PET tracers with polar but nonbasic linkers to image the fibroblast activation protein in the microenvironment of tumorsKöchel R, Schwegmann K, Breyholz HJ, Schäfers M, Wagner S, Wünsch BOpen paperThis study develops fluorine-18 PET tracers with polar, nonbasic linkers to image fibroblast activation protein in the tumor microenvironment.
Dynamic neuroimaging of intranasal-administered radiotracers to assess brain waste clearanceSmith K, Fan J, Gerdes J, Kessler R, Zinn KSearch for paperThis paper uses dynamic PET neuroimaging of intranasally administered radiotracers to assess waste clearance from the brain.
Multimodal imaging demonstrates antifibrotic effects of targeting αvβ6vβ1 integrins in biliary fibrosisZhou IY, Turner S, Boice A, Caravan P, Ning Y, Ay I, Rotile NJ, Schaub JROpen paperThis multimodal imaging study assesses the antifibrotic effects of targeting alpha-v-beta-6 and alpha-v-beta-1 integrins in biliary fibrosis.
Automated synthesis and initial evaluation of [18F]FBAT for PET/MR imaging of inducible nitric oxide synthaseYeh SHH, Huang WS, Chiu CH, Chen CL, Chen HT, Chi DY, et alOpen paperThis paper reports automated synthesis and initial evaluation of [18F]FBAT for PET/MR imaging of inducible nitric oxide synthase.
18F-FPP-RGD2 PET imaging for interrogating target engagement and antifibrotic activity of an integrin antagonist in a mouse model of metabolic dysfunction-associated steatohepatitisZhou IY, Zhang C, Sojoodi M, Rotile NJ, Lan Y, Barrett SC, et alOpen paperThis study uses 18F-FPP-RGD2 PET to measure integrin target engagement and antifibrotic activity in a mouse model of metabolic dysfunction-associated steatohepatitis.
High-throughput PET/MR imaging of rats and mice with transferable 3D-printed animal holdersSmith K, Zinn KSearch for paperThis paper presents transferable 3D-printed animal holders designed to increase throughput and consistency in PET/MR imaging of rats and mice.
Impaired brain glucose metabolism in glucagon-like peptide-1 receptor knockout miceLi H, Fang Y, Wang D, Shi B, Thompson GJOpen paperThis study investigates impaired brain glucose metabolism in GLP-1 receptor knockout mice, using metabolic imaging to characterize the neurological effect of receptor loss.
Performance evaluation of a PET of 7T Bruker Micro-PET/MR based on NEMA NU 4-2008 standardsDoss KKM, Mion PE, Kao YCJ, Kuo TT, Chen JCOpen paperThis technical paper evaluates the performance of a 7 T Bruker micro-PET/MR system according to NEMA NU 4-2008 standards.
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinomaSingh RR, Thotakura AK, Alati S, Lisok A, Jiang Z, Merino VF, Minn I, Yadav S, Markowski MC, Ged Y, et alOpen paperThis study assesses PSMA-targeted radiotheranostics in an experimental renal cell carcinoma model, using PET-compatible targeting to evaluate tumor uptake and therapeutic potential.
Development and characterisation of a thermoreversible sol-gel for intranasal delivery of MRI and PET imaging agentsAlmahmoud A, Parekh HS, Paterson BM, Tupally KR, Cowin GJ, Nguyen A, Gulzar A, Vegh VOpen paperThis paper develops a thermoreversible intranasal sol-gel formulation for delivering both MRI and PET imaging agents.
Species-specific hepatic uptake of [64Cu]Cu-EOB-NOTA: a newly designed hepatospecific PET agentFan J, Ramulu BJ, Mallett CL, Kenney LE, Kaufman N, Bhattacharyya T, et alOpen paperThis study characterizes the species-specific liver uptake of [64Cu]Cu-EOB-NOTA as a newly designed hepatospecific PET agent.
Imaging tumor and ascites-associated macrophages in a mouse model of metastatic ovarian cancerFoss CA, Wildes F, Mezzanzanica D, Podo F, Hung CF, Yadav S, Penet Vidaver MFOpen paperThis paper uses molecular imaging to visualize tumor-associated and ascites-associated macrophages in a mouse model of metastatic ovarian cancer.
PET/MRI and bioluminescent imaging identify hypoxia as a cause of programmed cell death ligand 1 image heterogeneityParkins KM, Krishnamachary B, Jacob D, Kakkad SM, Solaiyappan M, Mishra A, Mironchik Y, et alOpen paperThis multimodal study combines PET/MRI and bioluminescence imaging to identify hypoxia as a driver of heterogeneous PD-L1 imaging signals.
PET/MRI with 89Zr-labelled antibodies provides insights into altered antibody pharmacokinetics in the chick embryo modelBenčurová K, Gündel D, Kieler M, Friske J, Kopka K, Helbich TH, Hacker M, Mitterhauser M, Philippe C, Balber T, Brandt MROpen paperThis PET/MRI study uses zirconium-89-labeled antibodies to investigate altered antibody pharmacokinetics in the chick embryo model.
Quantifying glymphatic clearance with PET imaging of 18F-FDS in ratsBrown K, Smith K, Fan J, Zinn KSearch for paperThis study uses 18F-FDS PET to quantify glymphatic clearance in rats.
Quantitative accuracy of preclinical in ovo PET/MRI: influence of attenuation and quantification methodsBalber T, Benčurová K, Mayrhofer M, Friske J, Haas M, Kuntner C, et alOpen paperThis paper evaluates how attenuation correction and quantification methods affect the quantitative accuracy of preclinical in ovo PET/MRI.
Assessing PET performance, image quality, and attenuation correction in the presence of RF coils within a 9.4 T MRI for preclinical simultaneous imagingKuntner C, Friske J, Stessl A, Haas M, Breyer LL, Wanek T, et alOpen paperThis technical study examines PET performance, image quality, and attenuation correction when RF coils are present inside a 9.4 T MRI system used for simultaneous imaging.
Contrast-enhanced T1-weighted MRI, 11C-DPA-713 PET and 11C-CPPC PET as predictive imaging biomarkers of neuroinflammation in radiotherapy-induced brain injuryMaiti S, Yadav SK, Teitz M, Velarde E, Lee S, Lecksell K, et alOpen paperThis study compares contrast-enhanced T1-weighted MRI with 11C-DPA-713 and 11C-CPPC PET as predictive imaging biomarkers of neuroinflammation after radiation-induced brain injury.
Brown adipose tissue as a unique niche for islet organoid transplantation: insights from in vivo imagingSun A, Hayat H, Kenyon E, Quadri T, Amos D, Perkins K, et alOpen paperThis paper uses in vivo imaging to investigate brown adipose tissue as a transplantation site for islet organoids.
Evaluation of precalculated attenuation correction map for preclinical cardiac PET/MR using a 1H/23Na surface coilRida H, Guetlin M, Naveau M, Haas M, Lebrun A, Joubert M, Manrique AOpen paperThis technical study evaluates a precalculated attenuation correction map for preclinical cardiac PET/MR performed with a combined proton and sodium surface coil.
Combining DMI and [18F]FDG-PET can complement the assessment of metabolic dysfunction-associated fatty liver diseaseEhret V, Ustsinau U, Fürnsinn C, Scherer T, Starčuková J, Hacker M, Krššák M, Philippe COpen paperThis study combines deuterium metabolic imaging with [18F]FDG PET to provide complementary assessment of metabolic dysfunction-associated fatty liver disease.
Imaging of fibroblast activation protein in the microenvironment of tumors by 18F-labeled positron emission tomography tracers with increased polarityKöchel R, Wagner S, Breyholz HJ, Schäfers M, Schwegmann K, Wünsch BOpen paperThis paper develops more polar fluorine-18-labeled PET tracers for imaging fibroblast activation protein in the tumor microenvironment.